Language
English
Publication Date
3-1-2025
Journal
Arteriosclerosis, Thrombosis, and Vascular Biology
DOI
10.1161/ATVBAHA.124.319870
PMID
39817327
PMCID
PMC11864897
PubMedCentral® Posted Date
3-1-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression. Anti-inflammatory therapy, therefore, presents a unique dilemma for cancer survivors: while it may decrease cardiovascular risk, it might also promote cancer growth and metastasis by suppressing the immune response. Senescence presents a potentially targetable solution to this challenge; senescence increases the risk of both cancer therapy resistance and vascular disease. Exercise, notably, shows promise in delaying this premature senescence, potentially improving cancer outcomes and lowering vascular disease risk post-treatment. This review focuses on the long-term impact of cancer therapies on vascular health. We underscore the importance of modulating senescence to balance cancer treatment's effectiveness and its vascular impact, and we emphasize investigating the role of exercise-mediated suppression of senescence in improving cancer survivorship.
Keywords
Humans, Neoplasms, Cellular Senescence, Anti-Inflammatory Agents, Animals, Vascular Diseases, Inflammation, Antineoplastic Agents, Cancer Survivors, Exercise, Treatment Outcome
Published Open-Access
yes
Recommended Citation
Casso-Chapa, Bernardo; Vazquez González, Norma Alicia; Le, Nhat-Tu; et al., "Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease" (2025). The Brown Foundation: Institute of Molecular Medicine. 33.
https://digitalcommons.library.tmc.edu/molecular_med/33